Angiodynamics (ANGO) Common Equity (2011 - 2026)

Angiodynamics has reported Common Equity for 16 years, with the latest figure at $173.4 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 6.73% year-over-year to $173.4 million; the trailing twelve-month figure through Feb 2026 stood at $173.4 million (down 6.73% YoY), and the FY2025 full-year result was $183.0 million, down 11.0% from the prior year.
• Common Equity for Q1 2026 stood at $173.4 million, down from $176.3 million in the prior quarter.
• The five-year high for Common Equity was $429.7 million in Q1 2022, with the low at $173.4 million in Q1 2026.
• Historically, Common Equity has averaged $293.3 million across 5 years, with a median of $218.7 million in 2024.
• Annual changes were most pronounced in 2023 — Common Equity increased 3.32% — and 2024, when it slumped 54.05%.
• Angiodynamics' Common Equity stood at $408.0 million in 2022, then dropped by 1.65% to $401.2 million in 2023, then tumbled by 53.45% to $186.8 million in 2024, then fell by 5.59% to $176.3 million in 2025, then slipped by 1.69% to $173.4 million in 2026.
• The last three Common Equity figures came in at $173.4 million (Q1 2026), $176.3 million (Q4 2025), and $178.9 million (Q3 2025), per Business Quant data.